Latest Developments

Betting on Biologics
Richmond.com
May 13, 2008
READ MORE

MHRA Gives Green Light to Study of Insmed FOB
FDA News
April 30, 2008
READ MORE

Panel Debates Knotty Challenges Facing Follow-on Biologics
BioWorld
April 29, 2008
READ MORE

Buckets Of Money: Biosimilars & Billions Of Dollars
Pharmalot
April 24, 2008
READ MORE

Big Pharma May Be Big Player in Follow-On Biologics Market
The RPM Report
April, 2008
READ MORE

Surprise Players in Follow-On Biologics?
In Vivo
April 23, 2008
READ MORE

Drugs Cost Far More Than They Should
Milwaukee Journal Sentinel
April 19, 2008
READ MORE

Insmed to Initiate Phase I Study of Follow-on Biologic Drug
Pharmaceutical Business Review
April 17, 2008
READ MORE

Insmed Advances to Clinic with First Follow-On Biologic, INS-19
BioWorld
April 17, 2008
READ MORE

MHRA Gives Green Light to Study of Insmed FOB
FDA News
April 17, 2008
READ MORE

House Subcommittee Seeks Consensus on Follow-On Biologics
FDA News
April 16, 2008
READ MORE

When Drug Costs Soar Beyond Reach
New York Times
April 15, 2008
READ MORE

House Committee Asks Industry for Input on FDA Approval Process of Follow-On Biologics
Kaiser Daily Health Policy Report
April 9, 2008
READ MORE

Pallone, Deal Reach Out on Crafting Biologic Legislation
Congress Daily
April 9, 2008
READ MORE
Subscription Only

Competition in Biotech Can Bring Costs Down
Richmond Times-Dispatch
April 6, 2008
READ MORE

Potential Federal Drug Savings Could Propel Biosimilars Bill
FDA Legislative Watch
April 1, 2008
READ MORE

Spend Less? Congress May Like Biosimilars
Pharmalot
April 1, 2008
READ MORE

Momenta, Insmed May Gain From Biotech Generics Law
Bloomberg
March 27, 2008
READ MORE

Europeans Lead With Biosimilars
Pharmacy Times
March 26, 2008
READ MORE

Patent Expirations Could Mean Biologics Competition
Pharmacy Times
March 25, 2008
READ MORE

When a Drug Costs $300,000
New York Times
March 23, 2008
READ MORE

More Groups Demand Pathway For Biogenerics
Drug Topics News
March 24, 2008
READ MORE

Health Canada Publishes Draft Biosimilar Guidance
FDA News
March 24, 2008
READ MORE

Is Competition Coming? Interview with Insmed CEO Geoffrey Allan
The American
March 21, 2008
READ MORE

Medicare Report Makes Case for Biosimilars
FDA News
March 17, 2008
READ MORE

Lawmakers Submit New Biosimilar Proposal
Drug Industry Daily
March 17, 2008
READ MORE

Biogenerics Conference Addresses Scientific and Regulatory Issues Surrounding Biosimilars
BioPharm Bulletin
March 12, 2008
READ MORE

Report to the Congress: Medicare Payment Policy
MedPAC
March, 2008
READ MORE

Biologics build lobbying army for '09
Politico
March 11, 2008
READ MORE

GPhA sets sights on increasing access to generic medicines in 2008
Drug Topics
March 10, 2008
READ MORE

Cost-control plan: generics
Boston Globe
March 3, 2008
READ MORE

Biogenerics could save US$378 billion
Generics Bulletin
March 1, 2008
READ MORE

Battleground marked out in US biogenerics debate
Generics Bulletin
March 1, 2008
READ MORE

Orphaning Biotech? The Impact of Biosimilars on Biotech Investment
In Vivo
February, 2008
READ MORE

Generics -- and Biogenerics -- Are the Solution to Reducing Rising Health Care Costs, Says GPhA
Generic Pharmaceutical Association
February 26, 2008
READ MORE

Scientific and Legal Viability of Follow-on Protein Drugs
New England Journal of Medicine
February 21, 2008
READ MORE

Biotech Firm Sets Sights on Biosimilars
FDA News
February 20, 2008
READ MORE

HHS: FDA, Lawmakers Should Collaborate on Biosimilar Proposal
FDA News
February 20, 2008
READ MORE

PBMs, Purchasers Pushing Generic Initiatives
FDA News
February 20, 2008
READ MORE

New Report Identifies $378 Billion in Savings From Generic Biologics
Biotech IP Blog
February 20, 2008
READ MORE

Dr. Robert Shapiro Discusses Follow-on Biologics Report
Patent Docs Blog
February 19, 2008
READ MORE

Can Approval of Biogenerics Really Save Money?
Patent Baristas Blog
February 19, 2008
READ MORE

Biotech pushes for generics bill in 2008
Associated Press
February 14, 2008
READ MORE

Bush plan would allow generic biotech drugs
Chicago Tribune
February 14, 2008
READ MORE

Insmed Announces National Awareness Campaign Regarding Follow-on Biologics
PatentDocs Blog
February 13, 2008
READ MORE

FDA, Congress to Jointly Form Follow-on Biologics Proposal
BioWorld Today
February 8, 2008
READ MORE

ABOUT FACE: BUSH, BIOTECH FIRMS SEEK BIOSIMILARS AS GENERICS STALL
Inside Health Policy
February 8, 2008
READ MORE

Insmed education effort targets Congress, public
PR WEEK
8 February 2008
READ MORE

Insmed applauds US biosimilars moves
Pharma Marketletter
7 February 2008
READ MORE

Lawmakers Push for Biosimilar Legislation in New Healthcare Initiative
FDA News
February 7, 2008
READ MORE

Generic Drug Makers, Prescription Drug Firms Well-Positioned in Light of Election Uncertainty
AP
February 6, 2008
READ MORE

President's Request Would Give FDA $2.4 Billion in Fiscal 2009
FDA News
February 6, 2008
READ MORE

FDA $2.4B Budget Includes Follow-On Biologic Pathway
BioWorld Magazine
February 6, 2008
READ MORE

Insmed Takes Follow-On Biologics Push to the Web
The Pink Sheet Daily
February 5, 2008
READ MORE

Generic Pharmaceutical Association Releases Statement on FDA FY09 Budget
Generic Pharmaceutical Association
February 5, 2008
READ MORE

White House recognizes the importance of establishing a follow-on biologics approval pathway
Reuters
February 5, 2008
READ MORE

Lawmakers Push for Biosimilar Legislation in New Healthcare Initiative
FDA News
February 1, 2008
READ MORE

New lobbying strategy: Stall?
Politico
February 1, 2008
READ MORE

Congress, FDA need to free up path to generic biologics
St. Louis Post-Dispatch
January 9, 2008
READ MORE

Biotech as Bush bows out, Nature Biotechnology
Nature
January 1, 2008
READ MORE

Path may clear for biotech generics
Chicago Tribune
December 26, 2007
READ MORE

The U.S. Senate and House of Representatives are both considering legislation that would authorize the US Food and Drug Administration (Rockville, MD) to approve follow-on biologics.

In December of 2007, the House Committee on Energy and Commerce Subcommittee on Health asked its Members to submit questions to be responded to by various stakeholders regarding follow-on biologics legislation.